Big pharmacy at the end of the year to welcome the new send warm
Release time:
2020-08-14
Big Pharmacy Sends Warmth at the End of the Year
News 12# July 27 , Jianfeng Big Pharmacy, together with Jinhua Old Science and Technology Workers Association and Jinhua Charity Federation, officially opened the "Large-scale Health Consultation and New Year Sends Warmth at the End of the Year" at Jianfeng Big Pharmacy.
This warm theme event is divided into three sessions. The first event on 27 invited dermatology, endocrinology, orthopedics, pediatrics, surgery, obstetrics and gynecology, cardiovascular and other fields. Many well-known experts in Jinhua City have face-to-face and one-on-one exchanges with citizens to provide free health consultations for the general public. In the second event, experts from Jinhua Central Hospital, Maternal and Child Health Hospital and other major hospitals in Jinhua were invited to carry out a large-scale free clinic with one heart and a common Chinese heart into Wucheng, and some doctors and volunteers were organized to visit Tangxi Zhengushan Village, the twinning village of the group company, to provide free blood pressure measurement and health consultation services for the villagers, and to send consolation products to the three low-income households in the village. In the third event, experts from the Department of Cardiology were invited to carry out health lecture activities to popularize health knowledge such as the treatment and health care of common diseases in winter.
At the free clinic site, experts from the Jinhua Old Science and Technology Workers Association and major hospitals in Jinhua came to the scene early to provide citizens with health consultations on common diseases and chronic diseases, popularize medical knowledge and health knowledge, and According to personal circumstances, give suggestions on diseases, health concepts, scientific prevention, etc., and answer patients' questions and troubles. Jianfeng Pharmacy has also set up blood sugar, blood pressure and bone mineral density testing points on the spot. For residents with hidden dangers in blood sugar and blood pressure, the chronic disease specialist of the pharmacy also gives advice on diet and medication on the spot, explaining the harm and prevention of hypertension and diabetes, so as to improve the public's understanding of such diseases, so as to learn more about disease prevention and treatment, It also takes this opportunity to help you improve your health awareness.
This free clinic received more than ,300 person-times, which was unanimously affirmed by relevant personnel of the Municipal Charity Federation and the Old Association for Science and Technology, and also highly praised by the general public. As the service window of Jianfeng Pharmaceutical, Jianfeng Pharmacy has always been aiming at serving the public, hoping to contribute to the health of Jinhua citizens through the development of such activities. (Ni Yingzhen Xu Jingqun)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page